Pharmaceutical Technology

NOVEMBER 17, 2022

According to GlobalData analysis, specialist small molecule API capabilities such as containment or controlled substances are driving large contract manufacturing organisations (CMOs) to acquire facilities. Partnering with containment experts.

Containment 130

Containment Contamination Contract Manufacturing Production 130

Pharmaceutical Technology

SEPTEMBER 15, 2022

Research by GlobalData (Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition) shows that containment facilities are in high demand as the use of cytotoxic drugs continues to grow. What is driving the surge in demand for APIs? This adds costs and time to the processes involved.

Containment 130

Containment Manufacturing Production Contract Manufacturing 130

Pharmaceutical Technology

JULY 14, 2022

Pharmaceutical Technology looks at drugs and biologics with recent regulatory verdicts that will likely impact manufacturing volumes. In this ongoing series , we put a spotlight on contracts between pharma companies and contract manufacturing organizations (CMOs).

Manufacturing 130

Manufacturing Drugs Vaccine Vaccination 130

Roots Analysis

APRIL 15, 2024

It is worth noting that, any discrepancies encountered at this stage of manufacturing can lead to microbial contamination, subsequently resulting in loss of product, long development timelines and substantial financial burden for the drug developers, owing to the high cost of cell-derived raw materials.

Manufacturing 40

Manufacturing Production Contract Manufacturing Contamination 40

Roots Analysis

OCTOBER 24, 2023

Different Types of HPAPIs The new generation of APIs being developed are highly complex in nature, including peptides, HPAPIs, oligonucleotides and sterile APIs. This precaution is taken to prevent any potentially harmful contaminant from escaping the production area.

Manufacturing 40

Manufacturing Hormones Contamination Containment 40

Roots Analysis

JANUARY 12, 2023

The focus of stakeholders has now shifted to optimizing the cell therapies manufacturing process. For instance, in case of an autologous cell therapy ; the first step involves the procurement of input material (cells) from the patient, since these therapies are developed using the patient’s own cells.

Manufacturing 40

Manufacturing Production Contamination Medicine 40

The Pharma Data

JANUARY 27, 2021

The two-hour event will cover various topics, including an overview of the Company’s board and executive leadership, its commitment to environment, social and governance (ESG) matters, and progress updates on the Company’s critical care programs, manufacturing and distribution approach, and commercial readiness plans. 28, 2021 11:00 UTC.

Clinical Trials 52

Clinical Trials Clinical Trials Production Trials 52